AgingResearch.NewsJoin free

NMNAT1 gene therapy

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Howard Hughes Medical Institute and 2 more
  • Animals1

Outcomes

1

Glaucoma

downin mice1

1 study

  1. NMNAT1 gene therapy protects against glaucoma in mice.

    “gene therapy (driving expression of Nmnat1, a key NAD+-producing enzyme), was protective both prophylactically and as an intervention.”

    Animalsglaucoma-prone mice; prophylactic and interventional administration, alone and/or with nicotinamidedriving expression of Nmnat1eye

    Vitamin B₃ modulates mitochondrial vulnerability and prevents glaucoma in aged mice

    Science (New York, N.Y.)17 Feb 2017

More on Glaucoma

Latest

Related